Richard Y. Ebright, MD, PhD

Oncology Fellow @DanaFarber and @MGHCancerCenter | @Forbes 30 Under 30 | oncology + precision medicine

[Richard Y. Ebright, MD, PhD @RYEbright]

How should we be drugging RAS and developing clinical combinations for RAS-driven tumors?

@andrewaguirremd, Alice Shaw, @Julien__Dilly, and I have a lot of thoughts (>15,000 words of thoughts), and our mega review is out now at @CD_AACR! Check it out: https://t.co/sUU5fzpM7f

[Cancer Discovery @CD_AACR]

Online now for the #AACR25 session on Advances in #KRAS Biology in PDAC by session speaker @andrewaguirremd: Response and Resistance to RAS inhibition in Cancer https://t.co/y2lwO3oXdz

[Richard Y. Ebright, MD, PhD @RYEbright]

Absolutely incredible to see the massive benefit of RAS inhibition in pancreatic cancer patients, changing the field as I finish my training!! Led by one of my clinical mentors, Brian Wolpin, and received with standing ovation.

Also very cool to be cited in the discussion :)

[Adam Feuerstein ✡️ @adamfeuerstein]

Incredible #ASCO26 moment.

Dr. Brian Wolpin, presenter of the daraxonrasib study, received a standing ovation DURING his talk after he stated the survival benefit for PDAC patients. It was sustained. Cheering. I have never see anything like it in the middle of a talk. $RVMD

[Richard Y. Ebright, MD, PhD @RYEbright]

A new standard for PDAC. Daraxonrasib with 13.2m OS in 2L, and next-generation molecules in development. #RAS

Incredible to see this field changing as I finish training.

Congrats to $RVMD, @NextechInvest + @schroederthilo, and to all the patients!!!

https://t.co/QSwHNJKJte

[Richard Y. Ebright, MD, PhD @RYEbright]

Happy to have contributed to this new work from @KathleenMulvan4 and @TheSellersLab, showing that KRAS and PRMT5 inhibitors synergy, out now in Cancer Research. KRAS/PRMT5 combos ($RVMD/$TNGX) are now in clinical trials, and results couldn't come sooner!
https://t.co/mIc6hkbMpL

[Richard Y. Ebright, MD, PhD @RYEbright]

So many important, practice-changing presentations at #ASCO25, but the best part was seeing the work of my incredible @DanaFarber co-fellows 🌟🌟🌟
@SaraKCharMD @SWaliany @tess_omeara @AshleyOdai

[Kimmie Ng, MD, MPH @KimmieNgMD]

No doubt the best GI Onc division on the planet! So grateful to work with brilliant, kind, and visionary colleagues #ASCO25 @DanaFarber @DanaFarberNews @DFarberYoungCRC @ASCO

[Richard Y. Ebright, MD, PhD @RYEbright]

Disgusting.

[The Boston Globe @BostonGlobe]

The Trump administration has moved to terminate scores of research grants at Harvard University and its medical school, imperiling scores of research projects and potentially upending the futures of dozens of young scientists. https://t.co/PXz91lOI0v

[Richard Y. Ebright, MD, PhD @RYEbright]

@OscarTahuahua Great summary, thanks for highlighting the review!👌👌

[Richard Y. Ebright, MD, PhD @RYEbright]

@aparna1024 @MGHCancerCenter @bostonmarathon @colinjoyproject Have a great race Aparna!!

[Reid Huber @ReidHuber]

56 FDA/CDER novel drug approvals in 2023 (+51% from 2022)

Accelerated approval: 9
Orphan drug designations: 18
Fast track designation: 16
Priority review: 24
Breakthrough therapy: 9

[Richard Y. Ebright, MD, PhD @RYEbright]

Congrats to the next wave of @DanaFarber / @MGHCancerCenter fellows!! An incredible group coming from @mghmedres! @MattMeiz @DylanJMartini @ben_ouyang @SiennaDurbin

[Richard Y. Ebright, MD, PhD @RYEbright]

@psrajendran87 @mghmedres @DOM_UCLA @uclaCVfellows @gcfmd @kewatson @datsunian @shivkumarmd Congrats Pradeep!! They’re lucky to have you!

[Richard Y. Ebright, MD, PhD @RYEbright]

@SamWattrus @BCHStemCell @MGH_RI Congrats Sam! Well deserved!!

[Richard Y. Ebright, MD, PhD @RYEbright]

@_emmarosewest @Forbes @jykishi Congrats Emma! Excited to see it grow!

[Richard Y. Ebright, MD, PhD @RYEbright]

@jmvyasmdphd @MGHMedicine @mghmedres Thank you @jmvyasmdphd for everything you’ve done for the residency, it was an incredible place to train during your tenure. Looking forward to seeing what you do next!

[Richard Y. Ebright, MD, PhD @RYEbright]

@DrWilliamHwang @MGHCancerCenter @MGH_RI @MGHCSB Congrats and well-deserved Will!

[Sarah Waliany, MD, MS @SWaliany]

So excited to start heme/onc fellowship @DanaFarber / @MGHCancerCenter with this phenomenal crew!

Grateful to my family, friends & mentors @StanfordDeptMed @Ron_Witteles @JoelNealMD @HanZhuMD @HwakeleeMD for helping me reach this next stage of my career

[Richard Y. Ebright, MD, PhD @RYEbright]

Beyond grateful to have had the opportunity to pursue residency at @MGHMedicine with the incredible mentors and coresidents at @mghmedres—so much growth and learning over the last few years.

Per my superlative, maybe one day I’ll put these lessons to use in my Ibiza-based lab 😂